STING1 and non-small cell lung carcinoma: Additionally, the STING agonists, DMXAA and 2′3′-cGAMP, can repolarize M2 bone marrow-derived macrophages to M1 macrophages in vitro, inducing tumor site-specific vascular disruption and reducing tumor burden in non-small cell lung cancer (NSCLC) mouse models (Figure 2A) (67).